Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 ...

Shares of Zoetis have been roughly average performers over the past decade. The shares seem appealingly valued at recent ...

The reality is that people and animals will always need medicine, treatments, and other products to live long and comfortable ...

Zoetis stock reversed Tuesday, sinking into the red, despite beating second-quarter expectations as Librela sales continued ...

Q2 2025 Management View Kristin C. Peck, CEO, reported "strong broad-based 8% organic operational revenue growth" and noted ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and ...

Meanwhile, the company has an impeccable dividend program. The company has increased its payouts by 502% over the past decade ...

Shares of Zoetis Inc. ZTS slipped 1.46% to $148.81 Wednesday, on what proved to be an all-around grim trading session for the ...

Zoetis Inc. closed 25.61% short of its 52-week high of $200.33, which the company reached on September 19th.

Zoetis's leadership, scale, and innovation position it well against new competitors. Click here to read more about ZTS stock and why it is a Buy.

Zoetis enjoys enviable financial flexibility, even as leverage ticked up in 2015 to finance the purchase of Pharmaq and Abbott's animal health business. With long-term debt at roughly $5.2 billion ...

Zoetis, a leading animal health company, has shown impressive growth with a 17.55% CAGR since its IPO. Read why I rate ZTS stock a Buy now.